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Abstract
Objective: Pigment epithelium-derived factor (PEDF) belongs to the serpin family of peptidase inhibitors (serpin F1) and is
among the most abundant glycoproteins secreted by adipocytes. In vitro and mouse in vivo data revealed PEDF as a
candidate mediator of obesity-induced insulin resistance. Therefore, we assessed whether common genetic variation within
the SERPINF1 locus contributes to adipose tissue-related prediabetic phenotypes in humans.
Subjects/Methods: A population of 1,974 White European individuals at increased risk for type 2 diabetes was characterized
by an oral glucose tolerance test with glucose and insulin measurements (1,409 leptin measurements) and genotyped for
five tagging SNPs covering 100% of common genetic variation (minor allele frequency $0.05) in the SERPINF1 locus. In
addition, a subgroup of 486 subjects underwent a hyperinsulinaemic-euglycaemic clamp and a subgroup of 340 magnetic
resonance imaging (MRI) and spectroscopy (MRS).
Results: After adjustment for gender and age and Bonferroni correction for the number of SNPs tested, SNP rs12603825
revealed significant association with MRI-derived total adipose tissue mass (p=0.0094) and fasting leptin concentrations
(p=0.0035) as well as nominal associations with bioelectrical impedance-derived percentage of body fat (p=0.0182) and
clamp-derived insulin sensitivity (p=0.0251). The association with insulin sensitivity was completely abolished by additional
adjustment for body fat (p=0.8). Moreover, the fat mass-increasing allele of SNP rs12603825 was significantly associated
with elevated fasting PEDF concentrations (p=0.0436), and the PEDF levels were robustly and positively associated with all
body fat parameters measured and with fasting leptin concentrations (p,0.0001, all).
Conclusion: In humans at increased risk for type 2 diabetes, a functional common genetic variant in the gene locus
encoding PEDF contributes to overall body adiposity, obesity-related insulin resistance, and circulating leptin levels.
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Introduction
Pigment epithelium-derived factor (MIM ID *172860), also
referred to as serpin F1 (human gene symbol: SERPINF1), belongs
to the serpin family of peptidase inhibitors. Even though this
serpin is unique in that its C-reactive loop is inactive and thus non-
inhibitory [1], PEDF was reported to exert multiple effects in vitro
and in mice in vivo including promotion of neuronal survival and
differentiation and potent inhibition of angiogenesis [2]. Originally
identified as a product of cultured human retinal pigment
epithelium cells, PEDF is thought to play a central role in the
development of the neural retina [3].
Recently, PEDF was identified as a bona fide adipokine by
lectin chromatography of culture media conditioned by 3T3-L1
adipocytes and subsequent mass spectrometric analysis [4]. Based
on peptide coverage in the mass spectra, PEDF accounted for
,20% of full-length proteins and thus turned out to be among the
most abundant glycoproteins secreted by 3T3-L1 adipocytes.
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e34035Later on, studies on the secretome of human adipocytes using two-
dimensional polyacrylamide gel electrophoresis of conditioned
media followed by mass spectrometric analysis confirmed PEDF as
one of the most abundant adipokines [5]. Furthermore, plasma
PEDF concentrations were shown to be significantly elevated in
human type 2 diabetes [6,7] and the metabolic syndrome [8,9]. In
genetically and diet-induced obese mice, adipose tissue PEDF
expression and plasma PEDF levels increased up to three-fold,
whereas liver and skeletal muscle expressed only modest amounts
of PEDF which did not increase upon obesity [4]. Caloric
restriction of diet-induced obese mice resulted in a marked
reduction in adipose tissue PEDF expression [4].
Based on experiments performed in vitro and in mice in vivo
using recombinant PEDF, it could be demonstrated that this
glycoprotein exerts direct short-term and indirect long-term effects
on insulin-sensitive tissues, such as skeletal muscle, adipose tissue
itself, and the liver [4,5]. For the short term, PEDF is postulated to
act via a cell surface receptor [10,11] to activate c-Jun N-terminal
kinase and extracellular signal-regulated kinases which in turn
phosphorylate insulin receptor substrate 1 (IRS-1) at serine
residues [4]. This is known to convert IRS-1 into an inhibitor of
the insulin receptor tyrosine kinase. In consequence, PEDF
treatment results in reduced in vivo insulin sensitivity, impaired
insulin and glucose tolerance, increased hepatic glucose produc-
tion, and decreased insulin-stimulated muscular glucose uptake in
the absence of altered plasma insulin levels [4]. For the long term
using miniosmotic pumps, PEDF was shown to increase adipose
tissue lipolysis [4], an effect most probably mediated via adipose
triglyceride lipase [12]. This promotes spill-over of free fatty acids
to skeletal muscle and liver and ectopic lipid deposition in these
tissues which promotes insulin resistance and reduced insulin-
stimulated muscular glucose uptake [4]. All the acute and chronic
effects could be blocked by a neutralizing anti-PEDF antibody [4].
Thus, PEDF represents a candidate mediator of obesity-induced
insulin resistance. Its importance for human obesity and insulin
resistance is however not well investigated. Therefore, we assessed
in 1,974 White European individuals at increased risk for type 2
diabetes whether common genetic variation (minor allele frequen-
cy [MAF]$0.05) within the SERPINF1 locus contributes to
adipose tissue-related prediabetic phenotypes, such as increased
body adiposity, obesity-related insulin resistance, and elevated
circulating levels of the adipokine leptin.
Materials and Methods
Ethics statement
Informed written consent to the study was obtained from all
participants. The study adhered to the Declaration of Helsinki,
and the study protocol was approved by the Ethics Committee of
the Medical Faculty of the Eberhard Karls University Tu ¨bingen.
Subjects
A study cohort of 1,974 White European individuals was
recruited from the ongoing Tu ¨bingen family study for type 2
diabetes that currently encompasses more than 2,000 participants
at increased risk for type 2 diabetes (non-diabetic individuals from
Southern Germany with family history of type 2 diabetes or
diagnosis of impaired fasting glycaemia) [13]. All participants
underwent the standard procedures of the study protocol including
assessment of medical history, smoking status and alcohol
consumption habits, physical examination, routine blood tests,
and an oral glucose tolerance test (OGTT). Selection of the
present study cohort was based on the absence of newly diagnosed
diabetes and the availability of complete sets of phenotype and
genotype data. The participants were not taking any medication
known to affect glucose tolerance or insulin secretion. From the
overall cohort, a subgroup of 486 subjects voluntarily agreed to
undergo a hyperinsulinaemic-euglycaemic clamp and a subgroup
thereof (N=340) additionally magnetic resonance imaging (MRI)
and spectroscopy (MRS). The clinical characteristics of the overall
cohort and the clamp and MRI/MRS subgroups are given in
Table 1.
OGTT
A standardized 75-g OGTT was performed after a 10-h
overnight fast, and venous blood samples were drawn at time-
points 0, 30, 60, 90, and 120 min for the determination of plasma
glucose and insulin concentrations [13].
Hyperinsulinaemic-euglycaemic clamp
After a 10-h overnight fast and a 60-min baseline period,
subjects received a priming dose of insulin followed by an infusion
(40 mU/m
2) of short-acting human insulin for 120 min. A
variable infusion of 20% glucose was started to maintain the
plasma glucose concentration at 5.5 mmol/L. Blood samples for
the measurement of plasma glucose were obtained at 5-min
intervals throughout the clamp, plasma insulin levels were
measured at baseline and in the steady state of the clamp [13].
Measurements of body fat content and distribution
Body mass index (BMI) was calculated as weight divided by
height squared (kg/m
2). Waist circumference (in cm) was
measured in the upright position at the midpoint between the
lateral iliac crest and the lowest rib. The percentage of body fat
was measured by bioelectrical impedance (BIA-101, RJL systems,
Detroit, MI, USA). In addition, total and visceral fat contents (in
% of body weight) were determined by MRI with an axial T1-
weighted fast-spin echo technique with a 1.5-T whole-body imager
(Magnetom Sonata, Siemens Medical Solutions, Mu ¨nchen,
Germany), as described earlier [14]. The intrahepatic lipid
content (in % of signal) was determined by localized STEAM
1H-MRS (TR=4 s, TE=10 ms, 32 scans) in the 7
th segment of
the liver, as formerly reported [15].
Laboratory measurements
Plasma glucose (in mmol/L) was determined using a bedside
glucose analyzer (glucose oxidase method, Yellow Springs
Instruments, Yellow Springs, OH, USA). Plasma insulin concen-
trations (in pmol/L) were measured by a commercial chemilumi-
nescence assay for ADVIA Centaur (Siemens Medical Solutions,
Fernwald, Germany) according to the manufacturer’s instructions.
Fasting plasma leptin (in ng/mL) and PEDF (in mg/ml)
concentrations were determined by enzyme-linked immunosor-
bent assays (Linco Research, St. Charles, MO, and BioVendor,
Heidelberg, Germany, respectively).
Selection of tagging single nucleotide polymorphisms
(SNPs)
Based on the publicly available phase III data of the
International HapMap Project derived from the CEU population
of Utah residents with ancestry from Northern and Western
Europe (release #28 August 2010, http://hapmap.ncbi.nlm.nih.
gov/index.html.en), we screened in silico the complete SERPINF1
gene spanning 15.6 kb (8 exons, 7 introns, located on human
chromosome 17p13.3) as well as 4 and 1.5 kb of its 59- and 39-
flanking regions, respectively (Figure 1). The SERPINF1 locus is
flanked 6.5 kb upstream by the SERPINF2 gene (on the same
SERPINF1 and Adipose Tissue Mass
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reverse DNA strand), but no linkage blocks within the screened
SERPINF1 locus region were found to overlap with these
neighbouring genes. Within the SERPINF1 locus, 30 informative
HapMap SNPs were present with 17 displaying MAFs$0.05. The
HapMap linkage disequilibrium (r
2) data of the 17 common SNPs
are schematically presented in Figure 1. Among these, five SNPs
were selected tagging all the other common SNPs within the locus
with an r
2.0.8 (100% coverage) based on Tagger analysis using
Haploview software (http://www.broadinstitute.org/scientific-
community/science/programs/medical-and-population-genetics/
haploview/haploview). As depicted in Figure 1, these five tagging
SNPs were rs11658342 (G/A) in intron 2, rs1136287 (T/C) in
exon 3 encoding the amino acid exchange Met72Thr, rs12603825
(G/A) in intron 3, rs2071021 (A/G) in intron 6, and rs6828 (C/T)
in exon 7 encoding the synonymous variation Tyr321Tyr.
Genotyping
DNA was isolated from whole blood using a commercial DNA
isolation kit (NucleoSpin, Macherey & Nagel, Du ¨ren, Germany).
The five SERPINF1 SNPs were genotyped using the Sequenom
massARRAY system with iPLEX software (Sequenom, Hamburg,
Germany). The genotyping success rates were $99.7%. The
Sequenom results were validated by bidirectional sequencing in 50
randomly selected subjects, and both methods gave 100% identical
results.
Calculations
Homeostasis model assessment of insulin resistance (HOMA-
IR) was calculated as {c(glucose[mmol/L])0 ? c(insulin[mU/
L])0}/22.5 with c=concentration [16]. The insulin sensitivity
index derived from the OGTT (ISI OGTT) was estimated as
proposed by Matsuda and DeFronzo [17]: 10,000/{c(glucose[m-
mol/L])0 ? c(insulin[pmol/L])0 ? c(glucose[mmol/L])mean ?
c(insulin[pmol/L])mean}
K. The insulin sensitivity index derived
from the hyperinsulinaemic-euglycaemic clamp (ISI clamp) was
calculated as glucose infusion rate necessary to maintain
euglycaemia during the last 60 min (steady state) of the clamp
(in mmol ? kg
21 ? min
21) divided by the steady-state insulin
concentration (in pmol/L).
Figure 1. Genomic region of human chromosome 17p13.3 harbouring the SERPINF1 gene and HapMap linkage disequilibrium data
of common (minor allele frequency $0.05) informative SNPs within this region. The SERPINF1 gene consists of 8 exons and 7 introns and
spans 15.6 kb from nucleotide position 1,612,009 to nucleotide position 1,627,617. The analyzed region additionally included 4 kb of the 59-flanking
region and 1.5 kb of the 39-flanking region. This genomic region did not overlap with other known gene loci. The locations of the five tagging SNPs
(highlighted by boxes) are indicated. Linkage disequilibrium data, i.e., r
2-values only, are presented as numbers in the diamonds (100=1.00) and
different diamond shadings (white – low linkage; black – high linkage; grey – in between).
doi:10.1371/journal.pone.0034035.g001
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Hardy-Weinberg equilibrium was tested using x
2 test. Linkage
disequilibrium (D9,r
2) between the tagging SNPs was analyzed
using the JLIN programme provided by the Western Australian
Institute for Medical Research (http://www.genepi.org.au/jlin).
All continuous variables not normally distributed were loge-
transformed prior to linear regression analysis. Multiple linear
regression analysis was performed using the least-squares method.
In the regression models, the trait of interest (measure of body fat
content or distribution, plasma PEDF concentration, glycaemia, or
insulin sensitivity) was chosen as dependent variable, the SNP
genotype (in the additive or dominant inheritance model) as
independent variable, and gender, age, and – when testing
glycaemia or insulin sensitivity – percentage of body fat as
confounding variables. Based on screening five non-linked tagging
SNPs in parallel, a p-value,0.0102 was considered statistically
significant according to Bonferroni correction for multiple
comparisons. We did not correct (i) for the tested traits of interest
since these were not independent and (ii) for the two inheritance
models applied because associations were considered reliable only
when observable in both models (at least significant in one model
and nominal in the other). In all subsequent analyses addressing
exclusively the effects of SNP rs12603825 in more detail, a p-
value,0.05 was considered statistically significant. To perform
these analyses, the statistical software package JMP 8.0 (SAS
Institute, Cary, NC, USA) was used. In the dominant inheritance
model, our overall study cohort was sufficiently powered (1-b$0.8)
to detect, for the five tagging SNPs, (unadjusted) effect sizes of
Cohen’d ,0.12, the clamp subgroup was sufficiently powered to
detect effect sizes of ,0.26, and the MRI/MRS subgroup to
detect effect sizes of ,0.30 (a,0.05; Figure S1) with Cohen’s d-
values of 0.2, 0.5, and 0.8 representing by convention small,
medium, and large effect sizes, respectively. Power calculations
were performed using G*power 3.0 software available at http://
www.psycho.uni-duesseldorf.de/aap/projects/gpower/.
Results
Characteristics of the study participants
The overall study population consisted of 1,974 non-diabetic,
relatively young (median age 39 y), and moderately overweight
(median BMI 27.6 kg/m
2) White Europeans. Two thirds of the
subjects were women, one third men. About 70% of the subjects
were normal glucose tolerant, 30% prediabetic: 11% had isolated
impaired fasting glycaemia, 10% isolated impaired glucose
tolerance, and 8.5% both disturbances of glucose homeostasis.
The clinical characteristics of the study participants are given in
Table 1.
Genotyping results
The 1,974 participants were genotyped for the five tagging
SNPs of the SERPINF1 gene locus (Figure 1) with genotyping
success rates $99.7%. All SNPs were in Hardy-Weinberg
equilibrium (p$0.14, all). The observed MAFs ranged from 0.27
to 0.38 and were pretty similar to those reported by the HapMap
consortium for the CEU population (Table S1). The genetic
linkage between the tagging SNPs ranged from ‘weak’ (D9=0.54,
r
2=0.06) to ‘moderate’ (D9=0.97, r
2=0.75, Figure 2).
SNP associations with body fat content and distribution
All SNP associations with body fat measures were studied after
adjustment for gender and age. In the overall cohort, the minor A-
allele of SNP rs12603825 was nominally associated with an
elevated percentage of body fat (measured by bioelectrical
impedance) in the dominant inheritance model (p=0.0182;
Table 2). In the additive model, only a trend was visible
(p=0.07; Table 2). However, this allele’s significant association
in the dominant model (p=0.0035) and nominal association in the
additive model (p=0.0155) with increased fasting leptin levels
supports this SNP’s impact on overall adiposity (see Table 2 for
raw data and Figure 3A for adjusted data). The adjusted effect size
for this SNP’s effect on plasma leptin was +1.54 ng/mL (+5.5%
relative to GG) per risk allele. Inclusion of bioelectrical
impedance-derived percentage of body fat in the multiple
regression analysis abolished this SNP’s association with plasma
leptin (p=0.2, additive and dominant model) showing that this
effect on leptin is mediated by fat mass. In addition, the A-allele of
rs12603825 revealed significant association in the dominant model
(p=0.0094) and nominal association in the additive model
(p=0.0250) with increased total adipose tissue mass, as measured
by MRI (see Table 2 for raw data and Figure 3B for adjusted
data). The adjusted effect size of SNP rs12603825 was +1.22% of
body weight (+4.1% relative to GG) per risk allele.
The SERPINF1 SNP rs12603825 was not significantly associ-
ated with increased BMI, waist circumference, visceral adipose
tissue mass, or intrahepatic lipids (p$0.2, all; Table 2).
The other SNPs did not show any reliable association with
measures of body fat content and distribution (Table 2).
SNP associations with glycaemia and insulin sensitivity
All SNP associations with measures of glycaemia and insulin
sensitivity were studied after adjustment for gender, age, and
bioelectrical impedance-derived percentage of body fat. None of
the SNPs revealed any significant effect on glycaemia or insulin
sensitivity (p$0.03, all; Table S2).
Figure 2. Linkage disequilibrium data of the five tagging SNPs
derived from the overall cohort (N=1,974). D9-values are marked
by red shadings (scale given at the top), r
2-values by blue shadings
(scale given to the right). The distances (in kb) between the tagging
SNPs are given at the bottom of the figure.
doi:10.1371/journal.pone.0034035.g002
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PLoS ONE | www.plosone.org 6 March 2012 | Volume 7 | Issue 3 | e34035To see whether SNP rs12603825 exerts an effect on insulin
sensitivity via its effect on body adiposity, we excluded percentage
of body fat as a confounder from the multiple regression analysis.
In the dominant inheritance model, the minor A-allele of SNP
rs12603825 was significantly associated with reduced clamp-
derived insulin sensitivity (p=0.0251), and this association was
completely abolished after inclusion of percentage of body fat in
the analysis (p=0.8; Table S2). This provides evidence for an
association of this SNP with insulin resistance via promotion of
body adiposity.
Functionality of SNP rs12603825
SNP rs12603825 is located in intron 3 of the SERPINF1 gene.
Thus, it is supposed to affect SERPINF1 transcription rather than
the function or stability of PEDF. To address whether this SNP is
functional, we first analysed in silico whether the SNP alters a
transcription factor binding site. Using publically available
prediction software (TFSEARCH at http://www.cbrc.jp/
research/db/TFSEARCH.html and TESS at http://www.cbil.
upenn.edu/cgi-bin/tess/tess?RQ=WELCOME), we analysed a
DNA region from 20 bp upstream to 20 bp downstream of the
SNP for putative transcription factor binding sites. However, no
binding sites for mammalian transcription factors could be
identified to be directly affected by the SNP.
Next, we assessed the in vivo functionality of SNP rs12603825
by testing whether the SNP influences the fasting plasma PEDF
levels that were measured in the MRI/MRS subgroup. After
adjustment for gender and age, the body fat-increasing A-allele of
SNP rs12603825 tended to associate with higher fasting plasma
PEDF in the additive inheritance model (p,0.1) and was
significantly associated with increased plasma PEDF concentra-
tions in the dominant model (p=0.0436; Figure 3C).
Notably, the plasma PEDF concentrations adjusted for gender
and age were very robustly and positively associated with BMI
(b=0.6860.10, p,0.0001), bioelectrical impedance-derived per-
centage of body fat (b=0.7560.14, p,0.0001), MRI-derived total
(b=0.8360.16, p,0.0001) and visceral (b=0.1260.03,
p,0.0001) adipose tissue mass, MRS-derived intrahepatic lipids
(b=0.8960.13, p,0.0001), and with fasting plasma leptin
concentrations (b=2.5060.56, p,0.0001).
Discussion
In this genetic study, we demonstrate in vivo functionality of the
common SERPINF1 variant rs12603825 and its influence on
overall adiposity with the minor A-allele representing the plasma
PEDF- and body fat-elevating risk allele. Why we could not detect
an impact of this SNP on BMI could have several reasons. One
conceivable explanation could be the relatively low age of the
subjects examined (median age 39 y), as it is well-known that in
young, physically active subjects BMI rather reflects muscle mass
than fat mass. Another reason could be this SNP’s modest effect
size on body adiposity of ,8% (AA versus GG) that is presumably
too small to be translated into significant changes in BMI at least
in our cohort of limited sample size. Interrogation of publically
available genome-wide analyses from the GIANT consortium
(http://www.broadinstitute.org/collaboration/giant/index.php/
GIANT_consortium_data_files) again failed to reveal a signifi-
cant association of SNP rs12603825 with BMI in approximately
250,000 subjects (p=0.9). The lack of association in this large
sample could be due to confounders, such as ethnicity,
environment, prediabetic status, and study methods, that were
not accounted for in this study [18]. Thus, replication of our
results in larger, very well phenotyped and controlled study
cohorts could help shed further light on this issue. Nevertheless,
our finding, confirmed by the use of different measures of body
adiposity (MRI-derived total adipose tissue mass, bioelectrical
impedance-derived percentage of body fat, and plasma leptin
concentration), is in line with earlier studies showing positive
associations of circulating PEDF with obesity in rodents [4] and
humans [9,19,20], with human type 2 diabetes [6,7] and the
metabolic syndrome [8,9].
Whether the intronic variant rs12603825 affects the function or
the expression of the gene product PEDF is currently unclear, but
altered SERPINF1 expression via modified transcription factor
binding to the DNA sequence affected by the nucleotide exchange
Figure 3. Association of SNP rs12603825 with fasting plasma leptin concentration (A), total adipose tissue mass (B), and fasting
plasma PEDF concentration (C). Adjusted data (means +SE) of the dominant inheritance model (GG versus GA+AA) are presented. Total adipose
tissue (AT) mass was measured by magnetic resonance imaging (N=340), plasma leptin (N=1,409) and PEDF (N=340) by enzyme-linked
immunosorbent assays (see Materials and Methods).
doi:10.1371/journal.pone.0034035.g003
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PLoS ONE | www.plosone.org 7 March 2012 | Volume 7 | Issue 3 | e34035would be a conceivable explanation. Using publically available
software tools, we were unable to identify predicted transcription
factor binding sites directly altered by the SNP. Since these tools
are however of limited precision, future in vitro studies are needed
to clarify whether the SNP influences the binding of transcription
factors to this intronic DNA sequence. According to the direction
of the effects (increased body adiposity and reduced insulin
sensitivity in A-allele carriers) and the supposed biological function
of PEDF, one might postulate that the A-allele represents a gain-
of-function nucleotide exchange.
Even though it is well-described for many adipokines (leptin,
interleukin-6, plasminogen activator inhibitor 1, etc.) that
increased fat mass results in elevated expression and secretion of
the adipokine, it is unknown how primary alterations in PEDF
expression/secretion, e.g., due to non-coding genetic variation in
SERPINF1, affects body fat mass. In vitro and in mice in vivo,
PEDF was reported to increase lipolysis in an auto-/paracrine way
[4,12], a property that could explain altered fat mass in carriers of
SNP rs12603825. However, we were not able to show any
association of SNP rs12603825 with lipolysis-derived free fatty
acid or glycerol levels in the fasting state or during the OGTT
(data not shown). Thus, the mechanism underlying the observed
association remains unclear and awaits further molecular inves-
tigations.
Our finding that the A-allele of SNP rs12603825 was
(nominally) associated with reduced clamp-derived insulin sensi-
tivity (adjusted effect size 211.7%, AA versus GG) and that this
association was completely abolished upon adjustment for body fat
is consistent with our working hypothesis which postulated a role
of PEDF in obesity-related insulin resistance, as derived from in
vitro and mouse studies [4,5]. Moreover, this result is in line with
recently published human data reporting association of increased
plasma PEDF concentrations with insulin resistance [19–21].
Since our finding did not reach the level of significance, replication
studies in larger cohorts (or consortia) with hyperinsulinaemic-
euglycaemic clamp data are required to confirm this SNP effect.
In conclusion, our study revealed that a functional common
genetic variant in the gene locus encoding PEDF contributes to
overall body adiposity, obesity-related insulin resistance, and
circulating leptin levels in humans at increased risk for type 2
diabetes. This may support a role of PEDF in the pathogenesis of
human obesity and obesity-related disorders, such as insulin
resistance and type 2 diabetes.
Supporting Information
Figure S1 Power statistics of the five tagging SNPs in
the overall cohort, the clamp subgroup, and the MRI/
MRS subgroup. The statistical power (1-b) and the smallest, still
detectable effect size (Cohen’s d) are plotted. By convention,
Cohen’s d-values of 0.2, 0.5, and 0.8 represent small, medium, and
large effect sizes, respectively. Due to the narrow range of minor
allele frequencies (0.27–0.38), the five SNPs form close bundles of
curves in the three groups.
(TIF)
Table S1 Minor allele frequencies of the five SERPINF1
tagging SNPs observed in the overall cohort compared to
HapMap CEU data. MAF – minor allele frequency; SNP –
single nucleotide polymorphism
(DOCX)
Table S2 Associations of SERPINF1 SNPs with glycae-
mia and insulin sensitivity (overall cohort and clamp
subgroup). Data are shown as unadjusted raw data (means
6SD). Prior to statistical analysis, all parameters were adjusted for
gender, age, and bioelectrical impedance-derived percentage of
body fat. padd – p-value, additive inheritance model; pdom – p-
value, dominant inheritance model; nominal associations are
marked by bold fonts. HOMA-IR – homeostasis model assessment
of insulin resistance; ISI – insulin sensitivity index; OGTT – oral
glucose tolerance test; SNP – single nucleotide polymorphism
(DOCX)
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